Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, describes the mechanism of action of pivekimab sunirine and outlines findings from a study investigating the efficacy of this agent in combination with azacitidine plus venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) (NCT04086264). After investigating several doses, an optimal dose and duration of the triplet regimen was determined. Overall, the study demonstrated that the novel combination was well tolerated and did not induce myelosuppression, while also eliciting anti-tumor activity. Dr Davar also highlights encouraging data around the overall response rate (ORR) and complete remission (CR) rate observed, especially in venetoclax-naïve patients and patients who harbor a FLT3 mutation. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.